Changes in US stocks | BlossomHill Therapeutics (BLSM.US) shares fell slightly after entering the US stock market and opening

Zhitongcaijing · 1d ago

The Zhitong Finance App learned that on Friday, BlossomHill Therapeutics (BLSM.US) entered the US stock market. As of press release, the stock had fallen more than 1% to $15.8. BlossomHill Therapeutics, headquartered in San Diego, California, was founded in 2020. The company focuses on developing small-molecule cancer drugs by identifying structural weaknesses in existing treatments and designing new compounds to overcome these weaknesses. The company's core candidate BH-30643 for epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC) is currently undergoing global phase 1/ phase II clinical trials. The company plans to hold a phase 1 clinical completion meeting with the US Food and Drug Administration (FDA) in the fourth quarter of 2026 to discuss recommended phase II clinical administration plans and potential accelerated approval pathways for some patients.